GlassScriptPhysician profile
Jelena Kao
NPI 1932242062
$1,061.23
in general payments reported to CMS, 2019-2025
17 companies · $732 in 2025
The $732 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.02 · 2020: $79.51 · 2021: $40.76 · 2022: $46.69 · 2023: $31.20 · 2024: $54.60 · 2025: $732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $787 · Education: $31.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $787.05 |
| Education | $31.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $241.08 | 2020-2025 | |
| Janssen Biotech, INC. | $146.92 | 2019-2025 | Erleada, Akeega, Balversa |
| Adaptive Biotechnologies Corporation | $137.40 | 2025 | Clonoseq |
| Novartis Pharmaceuticals Corporation | $113.45 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $82.22 | 2019-2025 | |
| Glaxosmithkline, LLC. | $66.63 | 2025 | Jemperli, Zejula |
| Daiichi Sankyo INC. | $50.22 | 2024-2025 | Enhertu |
| Servier Pharmaceuticals LLC | $38.80 | 2025 | |
| Gilead Sciences, INC. | $32.34 | 2021-2025 | Trodelvy |
| Tempus Ai, INC | $23.94 | 2025 | Xt Cdx |
| Merck Sharp & Dohme LLC | $22.03 | 2025 | Keytruda |
| Astrazeneca Pharmaceuticals LP | $20.70 | 2022 | |
| Alnylam Pharmaceuticals INC. | $19.44 | 2025 | Givlaari |
| Aadi Bioscience, INC. | $18.39 | 2025 | Fyarro |
| Adc Therapeutics America, INC. | $18.08 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $17.30 | 2025 | Xtandi |
| Seagen INC. | $12.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jelena Kao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.